Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
RPT193
Placebo
Locations
14
United States
Pinnacle Research Group, LLC
Anniston, Alabama, United States
Perseverance Research Center LLC
Scottsdale, Arizona, United States
University Clinical Trials, Inc
San Diego, California, United States
Lenus Research & Medical Group
Miami, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Start Date
August 12, 2019
Primary Completion Date
April 26, 2021
Completion Date
April 26, 2021
Last Updated
September 30, 2021
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
RAPT Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions